Evolus (EOLS) Capital Expenditures Growth (3y) (2021 - 2026)
Evolus (EOLS) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.63 Bn | 30.69 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.04 Bn | 20.89 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn | 28.56% |
| 10 | Evolus | 400.57 Mn | 350.78 Mn | 48.90 Mn | -62.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.47% |
| Dec 31, 2025 | -7.43% |
| Sep 30, 2025 | 51.49% |
| Jun 30, 2025 | 92.31% |
| Mar 31, 2025 | 198.45% |
| Dec 31, 2024 | 40.41% |
| Sep 30, 2024 | -36.07% |
| Jun 30, 2024 | 610.06% |
| Mar 31, 2024 | 231.93% |
| Dec 31, 2023 | 57.09% |
| Sep 30, 2023 | 33.31% |
| Jun 30, 2023 | -41.07% |
| Mar 31, 2023 | 10.55% |
| Dec 31, 2022 | 853.91% |
| Jun 30, 2022 | 4.43% |
| Dec 31, 2021 | -302.76% |
| Sep 30, 2021 | 302.76% |
| Jun 30, 2021 | -30.66% |